



GOOD PEOPLE
for GOOD HEALTH

August 6, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Ref: Change in Director – Re-appointment of Chief Executive Officer and Whole-time Director

This is to inform you that the members of the Company at its meeting held today has appointed Mr. Nikhil Chopra (DIN: 07220097) as the Chief Executive Officer and Whole-time Director of the Company for a period of 5 years commencing from October 5, 2025.

Details as required under Regulation 30 of the Listing Regulations and the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended from time to time are given below.

Sr. No.	Disclosure requirement	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment
2	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment	October 5, 2025 Mr. Nikhil Chopra's current term as Chief Executive Officer and Whole-time

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

		<p>Director of the Company ends with effect from close of business hours on October 4, 2025. The members of the Company approved re-appointment of Mr. Nikhil Chopra (DIN: 07220097) as the Chief Executive Officer and Whole-time Director of the Company for a period of 5 years from October 5, 2025 to October 4, 2030.</p> <p>Mr. Nikhil Chopra is not debarred from holding the office of Director by virtue of any Order passed by SEBI or any other such authority.</p>
3	Brief profile	As per the Annexure
4	Disclosure of relationships between directors	Mr. Nikhil Chopra is not related to any other Director of the Company.

We request you to take the above disclosure on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

Annexure

Brief Profile of Mr. Nikhil Chopra:

Mr. Nikhil Chopra is a seasoned business leader in the pharmaceutical industry, currently serving as the CEO & Whole Time Director at JB Pharma since October 5, 2020. In this role, he is responsible for transforming the company and shaping its vision for 2026. With more than two decades of experience, Mr. Nikhil Chopra has consistently demonstrated his ability to drive sustainable growth and create significant shareholder value. As a visionary leader, Mr. Nikhil Chopra excels in assembling talented teams to address challenges and turn them into opportunities. His leadership style is marked by a focus on innovation, quality treatment, and improving medicine accessibility. Mr. Nikhil Chopra has been instrumental in introducing groundbreaking ideas to enhance access to high-quality treatments, positioning JB Pharma as the fastest-growing company among the top 25 in the pharmaceutical industry, for two consecutive years!

Under his guidance, JB Pharma has achieved an outstanding growth rate of 16%, surpassing the industry average of 10% as per IQVIA MAT Dec'23 data. Mr. Nikhil Chopra strategic approach includes spearheading inorganic acquisitions and transforming them into successful businesses, enabling the company to venture into progressive therapies such as heart failure, probiotics, cardiac care and ophthalmology and create better accessibility. This aggressive strategy has elevated JB Pharma to one of the top 10 players in cardiology therapy in the Indian pharmaceutical market and the leader in the hypertension segment. As a result of his dynamic strategy and foresight, the company's revenue nearly doubled, reaching INR 3000+ crore in FY23, with 6 of its major brands ranking in the top 300 Indian pharmaceutical brands. JB is amongst the Top 5 largest manufacturers of lozenges, globally!

Mr. Nikhil Chopra is an advocate for sustainable business practices. Under his stewardship, JB Pharma released its second Sustainability Report, underscoring the commitment to embedding responsible practices across all operations and ensuring transparency in the company's progress toward its ESG (Environmental, Social, and Governance) objectives.

At JB, he has played an instrumental role in leadership development programmes and fostering cross-functional collaborations within the organization. Another impactful initiative

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

was the enhancement of training programs for field force, emphasizing sales force automation and excellence by equipping the field force with cutting-edge technological tools, including digital promotion capabilities. Today JB Pharma boasts a strong India field force of 3000+ with therapy focused segmentation. Mr. Nikhil Chopra is also a catalyst for change in the industry, introducing the concept of 'Beyond The Pill' marketing. This involves implementing “phygital” initiatives to enhance patient awareness, education, diagnosis, and adherence. He has played a crucial role in talent development and fostering cross-functional collaborations within the organization.

Prior to JB Pharma, Mr. Nikhil Chopra served as the CEO-India Business at a leading pharmaceutical company for an impressive 24 years. His dedication, strategic vision, and industry expertise have positioned him as a prominent figure in the pharmaceutical sector, leading JB Pharma towards a successful and transformative future.

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com